Two clinical studies confirm Amicapsil’s effect on pressure injuries
Two clinical studies confirm
Amicapsil’s effect on pressure injuries

Download Publication

Download Publication

Both studies find 100% closure rates
for acute and chronic pressure injuries

Slider-web-AMR
See video, where Lady-Marie from UK Spinal Injuries Association describes how Amicapsil has treated her pressure injuries
Slider-web-pain-etc

Effective on antibiotic and antiseptic resistant wound infections.
Effective in immunocompetent and immunocompromised persons.

Slider-web-hypoallergenic
Hypoallergenic

Only natural ingredients

Only natural ingredients

Only natural ingredients

Slider-web-AMR
Antibiotics reduce the amount of carbon that can be stored in soil. This directly increases CO2 in the atmosphere and contributes to climate change.
One course of antibiotic release the same amount of carbon as a car driving around Earth 1.47 times.
Slider-web-Pollution
MPPT is environmentally sustainable:
it is biologically recyclable and does not require the use of chemicals, plastics or antimicrobials.
previous arrow
next arrow

Willingsford Ltd.

Willingsford is a British healthcare company. It was founded in 2010 for the purpose of pursuing MPPT in wound healing.

At the time, studies had demonstrated that the technology was effective in wound healing, but for commercialisation, the technology still had a long way to go. The mode-of-action was not completely understood, it was necessary to develop the manufacturing process and to achieve regulatory approval. Willingsford was therefore established and with the help of a UK government grant, the goal of gaining the CE-mark was achieved in July 2016.

Following approval, products based on MPPT were launched in the UK and the rest of Europe.

In March 2017, Willingsford received a second UK government grant to support the further development of MPPT.

Since launch, MPPT has been used by several hospitals and in community care and it has been able to promote the healing of a number of “non-healing” wounds. Many have described MPPT as a disruptive technology because it is based on completely new principles and because it can help wounds that no longer could be helped by existing approaches. However, its novelty also means that its acceptance takes time. It has been estimated that it takes around 9-10 years for a new technology to be fully accepted by the medical profession.

MPPT is available for human and veterinary wound healing in the EU and efforts to seek regulatory approval in other territories are ongoing.

In parallel with these activities, Willingsford is actively pursuing a number of other healthcare technologies.

Willingsford is looking for partners and distributors around its wound healing technology.